Kin Meng Wong

TauRx Pharmaceuticals Ltd. developes drugs and diagnostics for neurodegenerative diseases. its pipeline includes LMTX, a tau aggregation inhibitor (TAI) for Alzheimer?s and Behavioural variant frontotemporal dementia diseases; anti-synuclein, a synuclein protein; early-stage compounds for use in therapies for neurodegenerative diseases; and diagnostic tests that assist clinicians in detecting and confirming the nature of a disease and monitoring the effects of therapy. The company was founded by Claude Wischik in 2002 and is headquartered in Singapore.

TauRx Pharmaceuticals Ltd. developes drugs and diagnostics for neurodegenerative diseases. its pipeline includes LMTX, a tau aggregation inhibitor (TAI) for Alzheimer?s and Behavioural variant frontotemporal dementia diseases; anti-synuclein, a synuclein protein; early-stage compounds for use in therapies for neurodegenerative diseases; and diagnostic tests that assist clinicians in detecting and confirming the nature of a disease and monitoring the effects of therapy. The company was founded by Claude Wischik in 2002 and is headquartered in Singapore.

TauRx Pharmaceuticals Ltd. developes drugs and diagnostics for neurodegenerative diseases. its pipeline includes LMTX, a tau aggregation inhibitor (TAI) for Alzheimer?s and Behavioural variant frontotemporal dementia diseases; anti-synuclein, a synuclein protein; early-stage compounds for use in therapies for neurodegenerative diseases; and diagnostic tests that assist clinicians in detecting and confirming the nature of a disease and monitoring the effects of therapy. The company was founded by Claude Wischik in 2002 and is headquartered in Singapore.

TauRx Pharmaceuticals Ltd. developes drugs and diagnostics for neurodegenerative diseases. its pipeline includes LMTX, a tau aggregation inhibitor (TAI) for Alzheimer?s and Behavioural variant frontotemporal dementia diseases; anti-synuclein, a synuclein protein; early-stage compounds for use in therapies for neurodegenerative diseases; and diagnostic tests that assist clinicians in detecting and confirming the nature of a disease and monitoring the effects of therapy. The company was founded by Claude Wischik in 2002 and is headquartered in Singapore.

TauRx Pharmaceuticals Ltd. developes drugs and diagnostics for neurodegenerative diseases. its pipeline includes LMTX, a tau aggregation inhibitor (TAI) for Alzheimer?s and Behavioural variant frontotemporal dementia diseases; anti-synuclein, a synuclein protein; early-stage compounds for use in therapies for neurodegenerative diseases; and diagnostic tests that assist clinicians in detecting and confirming the nature of a disease and monitoring the effects of therapy. The company was founded by Claude Wischik in 2002 and is headquartered in Singapore.

TauRx Pharmaceuticals Ltd. developes drugs and diagnostics for neurodegenerative diseases. its pipeline includes LMTX, a tau aggregation inhibitor (TAI) for Alzheimer?s and Behavioural variant frontotemporal dementia diseases; anti-synuclein, a synuclein protein; early-stage compounds for use in therapies for neurodegenerative diseases; and diagnostic tests that assist clinicians in detecting and confirming the nature of a disease and monitoring the effects of therapy. The company was founded by Claude Wischik in 2002 and is headquartered in Singapore.

TauRx Pharmaceuticals Ltd. developes drugs and diagnostics for neurodegenerative diseases. its pipeline includes LMTX, a tau aggregation inhibitor (TAI) for Alzheimer?s and Behavioural variant frontotemporal dementia diseases; anti-synuclein, a synuclein protein; early-stage compounds for use in therapies for neurodegenerative diseases; and diagnostic tests that assist clinicians in detecting and confirming the nature of a disease and monitoring the effects of therapy. The company was founded by Claude Wischik in 2002 and is headquartered in Singapore.

TauRx Pharmaceuticals Ltd. developes drugs and diagnostics for neurodegenerative diseases. its pipeline includes LMTX, a tau aggregation inhibitor (TAI) for Alzheimer?s and Behavioural variant frontotemporal dementia diseases; anti-synuclein, a synuclein protein; early-stage compounds for use in therapies for neurodegenerative diseases; and diagnostic tests that assist clinicians in detecting and confirming the nature of a disease and monitoring the effects of therapy. The company was founded by Claude Wischik in 2002 and is headquartered in Singapore.

TauRx Pharmaceuticals Ltd. developes drugs and diagnostics for neurodegenerative diseases. its pipeline includes LMTX, a tau aggregation inhibitor (TAI) for Alzheimer?s and Behavioural variant frontotemporal dementia diseases; anti-synuclein, a synuclein protein; early-stage compounds for use in therapies for neurodegenerative diseases; and diagnostic tests that assist clinicians in detecting and confirming the nature of a disease and monitoring the effects of therapy. The company was founded by Claude Wischik in 2002 and is headquartered in Singapore.